{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:49:33Z","timestamp":1770518973674,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clinthera.2019.11.008","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:14:12Z","timestamp":1577142852000},"page":"94-107.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device"],"prefix":"10.1016","volume":"42","author":[{"given":"Juan Pablo","family":"Frias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Loizeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Merino-Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Alice","family":"Raudenbush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela","family":"Batsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.11.008_bib1","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.11.008_bib2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.11.008_bib3","author":"US Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.clinthera.2019.11.008_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A\u00a0phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2019.11.008_bib5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.clinthera.2019.11.008_bib6","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2019.11.008_bib7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.11.008_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jval.2015.09.2937","article-title":"Development and content validity testing of a patient-reported treatment acceptance measure for use in patients receiving treatment via subcutaneous injection","volume":"18","author":"Tatlock","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.11.008_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jval.2016.09.2410","article-title":"Psychometric evaluation of a treatment acceptance measure for use in patients receiving treatment via subcutaneous injection","volume":"20","author":"Tatlock","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.11.008_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40744-017-0090-2","article-title":"Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.clinthera.2019.11.008_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1932296816668877","article-title":"Ease of use of the insulin glargine 300 u\/ml pen injector in insulin-naive people with type 2 diabetes","volume":"11","author":"Pohlmeier","year":"2017","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.clinthera.2019.11.008_bib12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1177\/193229680900300624","article-title":"Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia","volume":"3","author":"Carter","year":"2009","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.clinthera.2019.11.008_bib13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.clinthera.2015.07.008","article-title":"Patient and physician perspectives on mode of administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels","volume":"37","author":"Roth","year":"2015","journal-title":"Clin Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:28Z","timestamp":1758963148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0149291819305697"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.11.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}